Latil A - Search Results

1

The Cosmetics Europe strategy for animal-free genotoxicity testing: project status up-date.

Pfuhler S, Fautz R, Ouedraogo G, Latil A, Kenny J, Moore C, Diembeck W, Hewitt NJ, Reisinger K, Barroso J. Pfuhler S, et al. Among authors: latil a. Toxicol In Vitro. 2014 Feb;28(1):18-23. doi: 10.1016/j.tiv.2013.06.004. Epub 2013 Jun 27. Toxicol In Vitro. 2014. PMID: 23811264 Free article.

2

Use of human in vitro skin models for accurate and ethical risk assessment: metabolic considerations.

Hewitt NJ, Edwards RJ, Fritsche E, Goebel C, Aeby P, Scheel J, Reisinger K, Ouédraogo G, Duche D, Eilstein J, Latil A, Kenny J, Moore C, Kuehnl J, Barroso J, Fautz R, Pfuhler S. Hewitt NJ, et al. Among authors: latil a. Toxicol Sci. 2013 Jun;133(2):209-17. doi: 10.1093/toxsci/kft080. Epub 2013 Mar 28. Toxicol Sci. 2013. PMID: 23539547

3

Presence of SARS-CoV-2 in a Cornea Transplant.

Otmani Idrissi M, Baudoin JP, Chateau AL, Aherfi S, Bedotto-Buffet M, Latil A, Lepidi H, Chiaroni J, Picard C, Mege JL, La Scola B, Mezouar S. Otmani Idrissi M, et al. Among authors: latil a. Pathogens. 2021 Jul 24;10(8):934. doi: 10.3390/pathogens10080934. Pathogens. 2021. PMID: 34451398 Free PMC article.

4

Étude exploratoire de l'activité de l'ELSSr (PERMIXON(®)) et de la Tamsulosine sur les biomarqueurs de l'inflammation dans le traitement des troubles urinaires liés à l'hyperplasie bénigne de la prostate.

Latil A, Rouquet J, Bunouf P, Petrissans M, Robert G, De la Taille A. Latil A, et al. Prog Urol. 2014 Nov;24(13):793. doi: 10.1016/j.purol.2014.08.025. Epub 2014 Oct 30. Prog Urol. 2014. PMID: 26461552 French. No abstract available.

5

Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.

Latil A, Pétrissans MT, Rouquet J, Robert G, de la Taille A. Latil A, et al. Prostate. 2015 Dec;75(16):1857-67. doi: 10.1002/pros.23059. Epub 2015 Aug 26. Prostate. 2015. PMID: 26306400 Free PMC article. Clinical Trial.

6

Anti-inflammatory properties of Lipidosterolic extract of Serenoa repens (Permixon®) in a mouse model of prostate hyperplasia.

Bernichtein S, Pigat N, Camparo P, Latil A, Viltard M, Friedlander G, Goffin V. Bernichtein S, et al. Among authors: latil a. Prostate. 2015 May;75(7):706-22. doi: 10.1002/pros.22953. Epub 2015 Feb 14. Prostate. 2015. PMID: 25683150

7

Public biobanks: calculation and recovery of costs.

Clément B, Yuille M, Zaltoukal K, Wichmann HE, Anton G, Parodi B, Kozera L, Bréchot C, Hofman P, Dagher G; EU-US Expert Group on cost recovery in biobanks. Clément B, et al. Sci Transl Med. 2014 Nov 5;6(261):261fs45. doi: 10.1126/scitranslmed.3010444. Sci Transl Med. 2014. PMID: 25378642

8

Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro.

Latil A, Libon C, Templier M, Junquero D, Lantoine-Adam F, Nguyen T. Latil A, et al. BJU Int. 2012 Sep;110(6 Pt B):E301-7. doi: 10.1111/j.1464-410X.2012.11144.x. Epub 2012 Apr 23. BJU Int. 2012. PMID: 22520557

9

[The mortuary: a place where lives can be saved].

Latil A, Roche I. Latil A, et al. Soins. 2011 Dec;(761):45-6. Soins. 2011. PMID: 22312685 French.

10

Molecular Validation of PACE4 as a Target in Prostate Cancer.

D'Anjou F, Routhier S, Perreault JP, Latil A, Bonnel D, Fournier I, Salzet M, Day R. D'Anjou F, et al. Among authors: latil a. Transl Oncol. 2011 Jun;4(3):157-72. doi: 10.1593/tlo.10295. Epub 2011 Jun 1. Transl Oncol. 2011. PMID: 21633671 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

57 results

Search Page